Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

pectations, and we are looking forward to taking the next steps toward bringing it to market for patients who need to improve their cholesterol levels. Our next step for the routine high cholesterol population is to conduct a longer-term Phase 2 study in patients in combination with statins, in which we expect to use induction doses of 200 to 300 mg/week and define maintenance doses in the range of 100 to 200 mg/week."

ISIS 301012 Coadministered with Statins

This randomized, double-blinded, placebo-controlled, dose-escalation study initially included five weeks of treatment at doses of 30, 100, 200, and 300 mg/week. Because ISIS 301012 was well tolerated in these cohorts, the study was expanded to include a 400 mg/week five-week treatment group and two longer-term treatment cohorts; results of dose cohorts through 300 mg/week were presented previously, results from the 400 mg/week cohort were presented today, and results from the longer-term cohorts will be presented later in the year. Patients in the five-week study had median baseline LDL-C levels between 107 and 168 mg/dL and had been on stable doses of < / = 40 mg of simvastatin or atorvastatin for at least three months, with a median statin treatment duration of 4 years. At a dose of 400 mg/week, patients receiving ISIS 301012 achieved median reductions of 51% in apoB, 47% in LDL-C, and 35% in TG beyond the levels they had already achieved on stable statin doses. ISIS 301012 treatment had no effect on HDL-cholesterol levels (HDL-C).

Interestingly, in this short-term study, increasing the dose from 300 mg/week to 400 mg/week did not result in further lipid lowering activity represented as median % changes from baselines. This apparent plateau in % reductions may be due to the higher baseline values in the 300 mg/week cohort relative to the 400 mg/week cohort. Indeed, the 400 mg/week cohort did achieve lower median absolute levels of both apoB (55 mg/dL at 400 mg/week versus 61 mg/dL at 300 m
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:3/2/2015)... Calif. , March 2, 2015 Isis Pharmaceuticals, ... has earned a $15 million milestone payment from GSK related ... in patients with familial amyloid polyneuropathy (FAP).  ... with ISIS-TTR Rx , and plan to report data from ... have completed the fifteen months of dosing and are now ...
(Date:3/2/2015)... BETHESDA, Md. , March 2, 2015 ... on treating and preventing autoimmune diseases, announced today that ... (AMG 714) from Amgen (NASDAQ: AMGN ). ... has the rights to develop, manufacture and commercialize AMG ... . Concurrently, Amgen has been granted an exclusive ...
(Date:3/2/2015)... Texas , March 2, 2015   Lexicon ... biopharmaceutical company focused on developing breakthrough treatments for human ... 2014 financial results on Wednesday, March 4, 2015 before ... conference call and webcast to discuss clinical development progress ... end of 2014 at 10:00 a.m. Eastern Time on ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 2Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 3Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2
... plc (Nasdaq: JAZZ ) today announced several ... company,s leadership team. The appointments include: ... company and will serve as general counsel and an ... in March.  Ms. Hooper is currently a partner at ...
... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... a letter dated January 18, 2012 from The Nasdaq Stock ... from the Company,s Board of Directors effective January 4, 2012, ... Nasdaq,s requirement that its audit committee consists of at least ...
Cached Medicine Technology:Jazz Pharmaceuticals plc Announces New Executive Appointments 2Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement 2
(Date:3/2/2015)... California (PRWEB) March 02, 2015 Final ... of the TranStatic Volume 2 from Pixel Film Studios. , ... made exclusively for FCPX,” said Christina Austin, CEO of Pixel ... have in any Final Cut Pro X editors toolbox.” , ... to the next with media altering static scrambling effects from ...
(Date:3/1/2015)... Women’s Excellence is pleased to announce ... on their website. There are over 75 terms and phrases ... , “This gives our patients a better understanding of what ... they may not understand. With this resource, our patients are ... and find terms and phrases that they may not remember or ...
(Date:3/1/2015)... March 01, 2015 A federal ... http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to trial in ... a witness to provide testimony regarding the role ... of the Profemur device, Bernstein Liebhard LLP comments. ... Court, Northern District of Iowa on February 25th, ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured ... takes a look at the latest and coolest technology products ... NewsWatch and a technology expert, conducted the review and shared ... drinks. , According to Home Distillation of Alcohol, it's understood ... there’s a pretty cool product that’ll help anyone achieve a ...
(Date:2/28/2015)... Heart diseases are on the rise in India. ... population and 5 percent of rural adult population suffer ... of them require specialized investigation and treatment to prevent ... (CVD). , A division of Indian Business News Agency ... “Indian Coronary Stent Market Forecast to 2019”. The new ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... ... weight loss can be with HCG Diet Drops , ... (PRWEB) June 14, 2010 -- It is no secret that obesity has reached epidemic ... suffering from health problems as a result of the extra pounds. , , ,But thanks ...
... CerMedia ... the Cell-Pore product group previously owned and operated by NanoDynamics, Inc. ... Buffalo, NY (PRWEB) ... of the principal manufacturing and production assets, inventory and certain information of the Cell-Pore ...
... ... specialist in cosmetic, facial plastic, and reconstructive surgery, understands that women need options. With ... patients an alternative method to breast implant surgery. Natural breast augmentation allows patients the ... ...
... N.C. Monday, June 14, 2010 A new study ... shows that millions of cancer survivors are forgoing needed medical ... today in CANCER, a peer-reviewed journal of the ... long-term health and well-being of cancer survivors could suffer because ...
... ... medical and financial benefits. The Sit&SipTM bottle is engineered for easy and healthy performance. ... ... 15 - 20 million visits to the doctor each year in the U.S. Acute ...
... ... , ... The Primax Electronic Cigarette System is now available from Primevapor.com., , ,Primevapor has combined a ... These cartridges not only produce more flavor and more vapor, but use US manufactured, vegetable ...
Cached Medicine News:Health News:Thousands Drop The Weight For Good with HCG Diet Drops 2Health News:CerMedia Completes Purchase of Cell-Pore Principal Assets from NanoDynamics 2Health News:Del Mar Plastic Surgeon Dr. Maurice Sherman Now Offering Natural Breast Implant Alternatives 2Health News:Cost concerns prevent many cancer survivors from getting medical care 2Health News:Ear Infection is the Most Common Reason Why an American Child Sees the Doctor 2Health News:Ear Infection is the Most Common Reason Why an American Child Sees the Doctor 3Health News:Electronic Cigarettes Are Better Than Ever 2
The VPAP III is a complete system solution for sleep-disordered breathing (SDB), providing comfortable and effective bilevel treatment. The VPAP III is an effective business solution for clinicians, ...
... for the Separation and Measurement of ... Subfractions, ,The Lipoprint System is a ... components which are not routinely tested ... provides detailed results within the subfractions ...
... high resolution diagnostic test for cholesterol components which ... test procedure is simple and can be done ... is clearly flagged. A color coded profile is ... in red and the good HDL in green. ...
... Ammonia/Alcohol Control is intended as ... ammonia and ethanol assay methods. ... targeted at clinically significant levels ... values are provided for the ...
Medicine Products: